Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 8Neoplasms 2Carcinoma, Pancreatic Ductal 2Thromboembolism 1Stomach Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Adenocarcinoma 1Neoplasm Metastasis 1Metastatic Pancreatic Adenocarcinoma 1Esophageal Neoplasms 1Cholangiocarcinoma 1Adenocarcinoma 1

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 3Pancreaticoduodenectomy 2Oxaliplatin 2Irinotecan 2titanium silicide 1tislelizumab 1sonidegib 1paricalcitol 1mitazalimab 1lenvatinib 1ivosidenib 1irinotecan sucrosofate 1glucoraphanin 1devimistat 1Transurethral Resection of Prostate 1Tissue Banks 1Taxes 1Specimen Handling 1Saline Solution 1S 1 (combination) 1Ropivacaine 1Robotic Surgical Procedures 1Radiomics 1Positron Emission Tomography Computed Tomography 1Parturition 1PEGPH20 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Losartan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Ductal Adenocarcinoma × PEGPH20 × Gastrointestinal × Clear all
NCT04134468 2020-01-31

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡